KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $47.6 million.

  • Neogenomics' Accumulated Expenses fell 2380.25% to $47.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $47.6 million, marking a year-over-year decrease of 2380.25%. This contributed to the annual value of $47.6 million for FY2025, which is 2380.25% down from last year.
  • Latest data reveals that Neogenomics reported Accumulated Expenses of $47.6 million as of Q4 2025, which was down 2380.25% from $51.3 million recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Accumulated Expenses ranged from a high of $62.4 million in Q4 2024 and a low of $23.6 million during Q1 2021
  • Over the past 5 years, Neogenomics' median Accumulated Expenses value was $39.8 million (recorded in 2022), while the average stood at $42.4 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 7547.7% in 2021, then tumbled by 2380.25% in 2025.
  • Quarter analysis of 5 years shows Neogenomics' Accumulated Expenses stood at $38.3 million in 2021, then grew by 4.8% to $40.1 million in 2022, then surged by 32.44% to $53.2 million in 2023, then rose by 17.46% to $62.4 million in 2024, then dropped by 23.8% to $47.6 million in 2025.
  • Its Accumulated Expenses was $47.6 million in Q4 2025, compared to $51.3 million in Q3 2025 and $48.6 million in Q2 2025.